

# Inflammatory and toxic myopathies

Marinos C. Dalakas

Neuromuscular Diseases Section, National Institute of Neurological Disorders and Stroke,  
National Institutes of Health, Bethesda, Maryland, USA.

The major advances in the immunopathogenesis and treatment of inflammatory myopathies, and the main criteria that distinguish polymyositis (PM) from dermatomyositis (DM) or inclusion-body myositis (IBM) are presented. The origin and implications of the amyloid and ubiquitin deposits found within the vacuolated fibers of patients with IBM are considered. The pathogenesis of human immunodeficiency virus (HIV) and human T-cell lymphotropic virus (HTLV)-I-associated PM is presented, and the role of retroviruses in triggering PM, even in the absence of detectable viral genome within the muscle fibers, is discussed. In addition, three toxic myopathies with distinct morphologic, biochemical, or molecular characteristics, caused by zidovudine [azidothymidine (AZT) myopathy], the cholesterol-lowering-agent myopathy (CLAM), and the combination of blocking agents with corticosteroids are presented.

Current Opinion in Neurology and Neurosurgery 1992, 5:645–654

## Introduction

Clinical, histopathologic, immunologic, and therapeutic criteria emerging over the past 5 years have distinguished three major groups of inflammatory myopathies: polymyositis (PM), dermatomyositis (DM), and inclusion-body myositis (IBM). Diverse or opposing views among diagnosticians of different disciplines, as well as common errors in the definition, diagnosis, histology, immunopathology, and management of patients with these diseases prompted a recent review by Dalakas [1•]. This review introduced new clinical and diagnostic criteria to supercede the criteria proposed 17 years ago [2]. In the old criteria, the main diagnostic features — proximal muscle weakness, myopathic findings on the electromyogram, elevated creatine kinase levels, and muscle biopsy findings — had equal diagnostic weight, and the diagnosis of 'PM' was acceptable even without a diagnostic muscle biopsy. Consequently, IBM was overlooked, and non-inflammatory myopathies were often erroneously diagnosed as PM. The review discussed the clinical findings of DM, PM, and IBM as well as overlapping syndromes, immunopathogenetic mechanisms, the role of viruses, and therapy. Here, I shall therefore present only the background information necessary for discussion of new information represented in 1991–1992. I

shall discuss three recently identified toxic myopathies that are sometimes considered inflammatory myopathies; these disorders are related to the use of azidothymidine (AZD; zidovudine), cholesterol-lowering agents, or the combined use of neuromuscular blocking agents and corticosteroids.

## Inflammatory myopathies

### Dermatomyositis

DM is clinically distinct because of the characteristic rash; it is also immunopathologically unique because there is a complement-mediated intramuscular microangiopathy. Early in the disease, the C5b-9 membranolytic attack complex (MAC) is activated by antibodies bound to microvascular components [1•,3,4]. The MAC deposits may allow osmotic leakage from the endothelial cell, resulting in lysis and destruction of intramuscular capillaries. The loss of capillaries then leads to ischemia, muscle fiber destruction with patterns resembling microinfarcts, inflammation, and finally perifascicular atrophy. These changes are seen not only in the classic form of DM, but also in the so-called 'amyopathic DM' (DM sine myositis). Euwer and Southeimer [5•] described six

### Abbreviations

**AIDS**—acquired immune deficiency syndrome; **AZT**—azidothymidine (zidovudine); **CLAM**—cholesterol-lowering-agent myopathy;  
**DM**—dermatomyositis; **HIV**—human immunodeficiency virus; **HMG-CoA**—3-hydroxy-3-methylglutaryl coenzyme A;  
**HTLV**—human T-cell lymphotropic virus; **IBM**—inclusion-body myositis; **MAC**—membranolytic attack complex;  
**MHC**—major histocompatibility complex; **MRI**—magnetic resonance imaging; **mRNA**—messenger RNA;  
**mtDNA**—mitochondrial DNA; **PM**—polymyositis.

patients with amyopathic DM who had normal strength up to 2 years from the time skin lesions appeared, and suggested that amyopathic DM is a subset of DM affecting only the skin. Otero *et al.* [6], however, challenged this view after studying muscle biopsies of seven DM patients with normal muscle strength. The biopsies revealed sub-clinical myositis with histologic and immunopathologic characteristics identical to those of typical DM. They concluded that DM is a single disease with identical immunopathology affecting both skin and muscle, but to a varying degree among patients.

Anti-endothelial cell antibodies were found in the serum of eight out of 18 patients with DM, including six with interstitial lung disease [7]. It is not known whether these antibodies resulted from the MAC-mediated capillary destruction, or were primary, initiating the immune-mediated microangiopathy.

### Polymyositis

Polymyositis is still a diagnosis of exclusion; no unique clinical criteria have been identified [1•]. Observations in the past few years, however, suggest that most patients with an initial diagnosis of PM who have not responded to any form of immunotherapy most likely have IBM or 'something else'. In PM, the primary effector T cells surrounding or invading healthy muscle fibers are cytotoxic CD8<sup>+</sup> T cells that recognize heretofore unidentified muscle antigens in the context of major histocompatibility complex (MHC) class I expression [1•,8,9]. These lymphocytes seem to be cytotoxic and recognize muscle auto-antigens, as supported by the cytotoxic effect noted in cocultures of autologous myotubes with T-cell lines derived from the endomysial inflammatory cells [10•]. Although most of the CD8<sup>+</sup> T cells use the  $\alpha/\beta$  T cell receptor for antigen recognition, CD4<sup>-</sup> and CD8<sup>-</sup>  $\gamma/\delta$  cytotoxic T cells can also mediate muscle fiber injury [11].

Emslie-Smith and Engel [12•] described a new necrotizing myopathy in three patients. The histologic hallmark was a microangiopathy characterized by 'pipestem' with no other histologic or clinical signs suggestive of DM. None of the three patients responded to immunotherapies. This unique immune-mediated microangiopathy differs from PM, DM, or IBM, and emphasizes the need to search for immune markers in the muscle biopsies of patients with unusual histologic features.

The incidence of cancer is apparently increased in patients with DM, but not PM or IBM [13] (for a review see Dalakas [1•]). This view was recently challenged by Sigurgeirsson *et al.* [14•] in a retrospective study of patients with PM or DM identified from a national registry of Swedish patients who had been admitted to hospitals between 1963 and 1983. Compared with cancer patients from the Swedish cancer registry, there was an increased association with cancer for both PM and DM. These disquieting results can be attributed to several methodological problems: undocumented diagnosis, incomplete chart review (only 1 patient's chart was reviewed out of 10 patients included in the study), inclu-

sion for analysis at least 30% of patients with a diagnosis that did not satisfy even the reviewers' criteria for PM, grouping of children and adults, and use of population statistics rather than matched controls or patients with other neuromuscular diseases.

### Inclusion-body myositis

Distinct clinical signs and symptoms may point to the suspicion of IBM in a patient with presumed PM who has not responded to immunotherapies. The signs include: weakness of distal limb muscles, including the hand and feet, and, commonly, weakness of the deep finger flexors; asymmetric weakness, with marked wasting of selected muscle groups; and early onset of dysphagia. The diagnosis of IBM relies on muscle biopsy findings of rimmed vacuoles, eosinophilic cytoplasmic inclusions with 15 to 18 nm filaments, small angulated fibers, and endomysial inflammation characterized by CD8<sup>+</sup> cytotoxic T cells surrounding MHC-I antigen-expressing muscle fibers. Although these changes imply a T-cell-mediated cytotoxic process identical to that seen in PM [1•,8,9], patients with IBM are notoriously resistant to all therapies. Rare cases can be familial, with autosomal dominant inheritance in some families [15•].

Some histologic features of IBM, specifically the rimmed vacuoles and microfilamentous inclusions, are also found in Welander's distal myopathy, a dominantly inherited muscle disease of late onset [16]. Lindberg *et al.* [17•], therefore, compared patients with Welander's distal myopathy and patients with non-familial IBM matched for age. They concluded that the Welander syndrome is less disabling and differs from IBM by the absence of endomysial inflammation and the sparing of proximal muscles.

Of much interest are the amyloid filamentous deposits within muscle fibers of IBM patients. With Congo-red staining Mendell *et al.* [18•] found, green bi-refringent amyloid deposits adjacent to the vacuoles, in locations that corresponded to the IBM filaments. Askanas *et al.* [19•] found that the amyloid-positive material within the vacuoles reacted with antibodies to the  $\beta$ -amyloid protein, the protein sequenced from the amyloid deposited in the blood vessels of patients with Alzheimer's disease. The vacuolated muscle fibers also reacted with antibodies to ubiquitin, which was immunolocalized to the cytoplasmic tubulofilaments [20•]. Beta-amyloid-positive fibrils also co-localized with ubiquitin.

These observations may stimulate a change in attention from immunopathic to degenerative etiologies of IBM, but they also raise several questions. Ubiquitin, a 76 amino acid protein is present in the cytoplasm of all eukaryotic cells; it also has a proteolytic function that leads to non lysosomal degradation of abnormal or short-lived cellular proteins [21]. Ubiquitinated neurofilaments associated with abnormal degradation of cytoskeletal proteins have been found in areas of tissue damage in other chronic neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis. If normal cellular components are inappropriately ubiquitinated, resulting in

aggregates of non-functional proteins, inclusion bodies can be generated [22]. Ubiquitinated fibers, found not only in the vacuoles of IBM but also in the autophagic vacuoles of oculopharyngeal muscular dystrophy, distal myopathy, and hereditary vacuolar myopathy [20•], may represent non-specific degradation products associated with autophagia. Because both amyloid deposits and ubiquitinated material have been associated with autophagic vacuoles, they might have a common origin and, as suggested by Mendell *et al.* [18•], may result from modification of normal proteins within an acidic degradative vacuole. As for the origin of amyloid, analogy should also be drawn to dystrophic amyloidosis, an amyloid formation seen with local complications of chronic tissue damage, as in chronic cardiac valvular disease [23].

### Viruses and inflammatory myopathies

Several viruses, especially enteroviruses, have been linked to the pathogenesis of inflammatory myopathies, because many members of the picornaviridae family can cause myopathy in laboratory animals. The association of these viruses with the human disease, however, is circumstantial, unconvincing, and unconfirmed [1•]. A possible seasonal pattern in the onset of inflammatory myopathies has been interpreted as an indirect sign of environmental (viral) cause [24]. Using a sensitive and specific method based on the polymerase chain reaction, Leff *et al.* [25•] searched for nucleic acid sequences from Coxsackie virus, mumps virus, encephalomyocarditis virus, adenoviruses, human T-cell lymphotropic virus (HTLV) types I and II, and human immunodeficiency virus (HIV) in the RNA extracted from muscle biopsy specimens of 44 patients with PM, DM, or IBM. No viral sequences were detected in any of the muscles. It is therefore unlikely that these or closely related viruses persisted in the muscles, or provided a continuing stimulus for disease progression in these patients.

### Retroviruses and inflammatory myopathies

Five different retroviruses have been linked to inflammatory myopathies: HIV, HTLV-I, simian retrovirus type I, simian immunodeficiency virus, and the human foamy retrovirus [1•,26,27].

The immunopathogenesis of HIV-associated PM was studied by Illa *et al.* [28•], Lampert *et al.* [29], and Leon-Monzon and Dalakas [30•] in biopsies of 21 patients by means of immunocytochemistry, *in situ* hybridization, and the polymerase chain reaction using specific HIV antibodies, probes, and primers. Viral antigens were found in occasional interstitial mononuclear cells next to the muscle fibers, but not within the muscle fibers themselves. Similar findings were noted by Hantai *et al.* [31•] in the muscle biopsies from seven patients. In a quantitative analysis of lymphocyte subsets Illa *et al.* [28•] found that the predominant endomysial cells were CD8<sup>+</sup> cells and macrophages that invaded or surrounded healthy and MHC-I antigen-expressing muscle fibers. HIV-associated PM therefore is not related to di-

rect infection of the muscle fibers by the virus, but rather is the result of a T-cell-mediated and MHC-I-restricted cytotoxic process triggered by the virus [28•].

A similar mechanism was suggested for the PM of HTLV-I infection in a study of six patients by Dalakas *et al.* [32•]. They found HTLV-I expression in only occasional endomysial lymphoid cells and not within the muscle fibers. Like HIV-PM, the muscle fiber injury in HTLV-I-PM was initiated by CD8<sup>+</sup> cytotoxic T cells in the context of MHC-I expression by muscle fibers. Because the immunopathologic characteristics of PM in retrovirus-positive patients are identical to those of the PM in retrovirus-negative patients, we suggested that retroviruses may be leading candidates in the viral cause of inflammatory myopathies. In a persistent viral infection, activated cytotoxic T cells can lead to myositis by exposing, via lymphokines or cytokines released by the endomysial lymphoid cells infected with HIV or HTLV-I, normally hidden or newly surfacing antigens against which there is no self-tolerance. The endomysial inflammation may then become self-sustaining if it cannot be down-regulated by the host. Molecular antigenic mimicry may also be a mechanism of self-sensitization because some anti-ribonucleoproteins react with polypeptides encoded by the *gag* gene of retroviruses [33].

Human myoblasts and myotubes resist infection and transfection with intact HIV or HIV proviral DNA construct, not only with the virus alone but also with HIV-infected lymphocytes [34•]. Like mature muscle, myotubes lack the CD4 receptor, which explains the resistance of muscle to direct infection by the virus.

The human foamy retrovirus, although not pathogenic in humans, was associated with a destructive myopathy in transgenic mice carrying the *bel* region of the retrovirus [35•]. The transgene was expressed in the striated muscle, and viral RNA was present in the viable muscle fibers.

In addition to an immune-related inflammatory myopathy, some HIV-positive patients have had myoglobinuria, myasthenia gravis, or pyomyositis. Previously rare in Europe or North America. Pyomyositis is now occurring with increasing frequency in patients with the acquired immune deficiency syndrome (AIDS) [1•]. Two recent studies [36•,37•] described 11 new patients with pyomyositis, caused by gram-negative bacteria in one, and by *Staphylococcus aureus* in the others. Pyomyositis begins with low-grade fever, even without leukocytosis, and localized muscle pain, and swelling. Ultrasonography, magnetic resonance imaging (MRI), or computerized tomography reveals an enhancing lesion, often with a fluid density. The common colonization of HIV-positive patients with *S. aureus*, and the reduced chemotaxis and bactericidal activity of their neutrophils against *S. aureus*, may be responsible for the bacterial infection of the muscle [36•].

Numerous iron granules (muscle siderosis) were found in the muscle fibers, endothelial cells, and macrophages in 21 of 41 AIDS patients with myopathy [38•]. Muscle siderosis may be caused by dysfunction of macrophages, which in the late stage of HIV infection may be incapable

of removing the iron granules produced by the degradation of myoglobin [38•].

### Muscle imaging and inflammatory myopathies

In the past 2 years or so, the use of MRI, especially with a fat-suppressing imaging technique, has been advocated for the diagnosis and follow-up of patients with inflammatory myopathies [39•–42•]. This expensive procedure, however, is unnecessary to determine if a patient with PM or DM has improved, and its accuracy and validity in differentiating PM or DM from a non-inflammatory myopathy are questionable. The only clinically useful indication for muscle MRI is in the evaluation of HIV-associated focal PM, which led to the diagnosis in six out of 13 patients with AIDS [43•]. The characteristic radiologic sign was that of muscle abscess with a rim of increased signal intensity corresponding to margins between drainable pus and edematous tissue. The subcutaneous tissues appeared normal. Sparing the subcutaneous tissues was considered a useful radiologic sign to distinguish pyomyositis from diffuse soft-tissue swellings related to other conditions, such as lymphodema, venous thrombosis, cellulitis, or lymphoma, where both the muscle and the subcutaneous tissues are involved.

### Treatment

Treatment of the inflammatory myopathies with corticosteroids, and the use of non-steroidal immunosuppressive drugs for their 'steroid-sparing' effect were discussed in the recent review by Dalakas [1•], who stressed the need for controlled therapeutic studies separately for PM, DM, and IBM. The first double-blind controlled therapeutic trial in PM and DM patients using plasma exchange and leukopheresis was conducted by Miller *et al.* [44•] in 39 patients randomized to receive 12 treatments, over a 1-month period, of plasmapheresis, leukopheresis, or sham pheresis. Plasmapheresis and leukopheresis were ineffective, and the results were conclusive for patients with chronic and severe disease. This study was important because it should terminate the uncontrolled use of this expensive and risky procedure.

Cyclosporin was effective in an uncontrolled study of three patients with PM refractory to conventional therapy and one patient with DM [45•], but the conclusion that it may be considered as a first-line agent in the management of PM and DM is premature without a controlled study.

High-dose intravenous immunoglobulin, 2 g/kg/month, was effective in two uncontrolled trials in patients with PM or DM. In one trial, [46•] five patients with juvenile DM improved during a 9-month course of intravenous immunoglobulin, allowing steroids to be reduced or discontinued. In the other trial, 14 patients with chronic PM and six patients with DM had been unresponsive to previous therapies [47•]. Intravenous immunoglobulin, given in conjunction with prednisone, methotrexate, or plasmapheresis for a mean of 4 months, resulted in marked clinical improvements in 15 out of the 20 pa-

tients. Although its mode of action is unclear, intravenous immunoglobulin appears to be a promising new agent for both PM and DM. It is safe, and well tolerated, but expensive, and a controlled study is required to document efficacy. Separate studies for PM, DM, and IBM are now underway at the National Institutes of Health.

Cricopharyngeal myotomy improved the dysphagia in two patients with IBM [48•,49•]. When weakness of pharyngeal muscles is severe the generated hypopharyngeal pressure may be insufficient to trigger reflex relaxation of the cricopharyngeal muscle. By eliminating the zone of elevated pressure between the pharynx and the esophagus, myotomy can produce more efficient swallowing, and should therefore be considered in selected patients with IBM.

## Toxic myopathies

### Azidothymidine myopathy

The challenge of distinguishing the HIV-associated primary myopathy from that resulting from the use of AZT, now called zidovudine, has been resolved by identifying the unique histologic and biochemical features present only in AZT-treated patients [50]. The unique histologic features found in AZT myopathy are 'ragged red fibers' that imply structural mitochondrial abnormalities, subsarcolemmal or central accumulations of red granular material and longitudinal or circumferential 'red-rimmed cracks' that are seen with the trichrome stain, as well as pale granular degeneration, rods, endomysial inflammation, and increased neutral fat that are attributed to impaired mitochondrial control of fatty acid use. These morphologic features characterize what we now call the 'AZT fiber'.

Electron microscopic study of muscle biopsies from patients with HIV myopathy, who had never received AZT, and from patients with AZT myopathy confirmed the presence of ultrastructurally abnormal mitochondria only in the AZT groups [51•].

The clinical features of AZT myopathy are those of a generic myopathy, characterized by proximal limb weakness, myalgia predominantly in the thighs and calves, fatigue, myopathic changes on the electromyogram, and hyperCKemia, which often worsens with exercise. In a follow-up of 20 patients with AZT-myopathy [52•], myalgia resolved, strength improved or became normal, and spontaneous activity on the EMG decreased or disappeared 4 to 6 weeks after AZT was discontinued. Jay *et al.* [53] found that weight loss and elevation of serum lactate levels may herald the onset of AZT myopathy. AZT can cause myopathy not only at the originally recommended high doses, but also with the lower doses currently recommended by the USA Food and Drug Administration [53].

With detailed histochemical and electromicroscopic studies, Mhiri *et al.* [54•] also concluded that mitochondrial myopathy is caused by AZT and not HIV. They found reduced activity of mitochondrial enzymes in muscles,

including succinate-cytochrome c reductase (respiratory chain complex II and III) and cytochrome c oxidase (respiratory chain complex IV). In contrast, there was normal activity of the citrate synthase, an enzyme encoded by nuclear DNA.

In a definitive study, Arnaudo *et al.* [55••] demonstrated, by means of Southern blotting, that AZT reduces the muscle content of mitochondrial DNA (mtDNA), a condition called depletion. Nine AZT-treated patients with myopathy had as much as 78% reduction of muscle mtDNA compared with normal nuclear DNA. A repeat muscle biopsy in one patient showed that the depletion was reversible with discontinuation of the drug. AZT, a DNA chain terminator, causes mitochondrial myopathy by inhibiting the  $\gamma$ -DNA polymerase of the mitochondrial matrix, resulting in termination of the mtDNA chain.

In a subsequent study [51••], the depletion of mtDNA was confirmed by immunocytochemistry using antibodies to single- and double-stranded DNA, in serial sections stained first with trichrome and then with anti-DNA antibodies. The immunostainable mtDNA was dramatically reduced in the muscles of AZT-treated patients. By contrast, within the ragged red fibers of patients with mitochondrial encephalomyopathies, where there is proliferation of mitochondria that show mutations or deletions in mtDNA, the staining was increased, reflecting normal mtDNA content. In AZT-myopathy, the mitochondria also proliferate, but have fewer mtDNA copies per organelle, resulting in a shortage of energy within the cell and severe destruction of the muscle fiber.

The structurally abnormal mitochondria in the muscles of AZT-treated patients are impaired in oxidative metabolism, as shown by depression and delayed recovery of phosphocreatine on *in vivo*  $^{31}\text{P}$  magnetic resonance spectroscopy [56••]. Soueidan *et al.* [57] found very early depletion of phosphocreatine, even in patients who had normal strength and normal muscle histology on light microscopy; abnormal mitochondria were seen only with electron microscopy.

AZT causes mitochondrial myopathy not only in HIV infection but also in normal rats and human muscle cultures. Lamperth *et al.* [58•] found that normal human myotubes, 19 days after AZT treatment, exhibited abnormal mitochondria characterized by proliferation, enlargement, abnormal cristae, and electron-dense deposits in the matrix. Similarly, Herzberg *et al.* [59•] showed marked inhibition of myotube proliferation with reduction of the mitochondrial-encoded cytochrome c oxidase. When healthy rats were treated intraperitoneally with AZT, the animals lost weight and developed hyperCKemia, lacticacidemia, hyperglycemia, and abnormal mitochondria in skeletal and cardiac muscles, but not in liver [58••]. Muscles had the highest concentration of AZT. On the basis of oxygen consumption and respiratory activity, muscle mitochondria isolated from the AZT-treated rats had a decrease in state three of the respiration and were uncoupled. Lewis *et al.* [60••,61••] found structural abnormalities in the heart and skeletal muscle mitochondria in rats fed AZT. There was depletion of muscle mtDNA, depression of cytochrome b messenger RNA

(mRNA) (but not of sarcomeric or cytosolic mRNA or of mRNA-encoded nuclear polypeptides), and decreased synthesis of mitochondrial polypeptides.

AZT is a unique muscle mitochondrial toxin, causing depletion of muscle mtDNA, which results in myopathy. Some severe myopathies in childhood are characterized by depletion of mtDNA [62]; AZT may therefore serve as a model toxin for the study of molecular events in some mitochondrial encephalomyopathies.

### Cholesterol-lowering-agent myopathy

Several cholesterol- or lipid-lowering drugs have been implicated in causing an often reversible myopathy characterized by proximal limb weakness, myalgia, elevation of creatine kinase levels, and myopathic changes on the electromyogram consisting of fibrillation potentials and myotonic or complex repetitive discharges [63–66]. Muscle biopsy usually shows non-specific changes or type II muscle fiber atrophy. Rarely, there are necrotic fibers without inflammation [66]. The implicated cholesterol-lowering agents include: fibric acid derivatives, such as fenofibrate, clofibrate, gemfibrozil (Lopid), and bezafibrate; nicotinic acid (niacin); dizacholesterol; and the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, such as lovastatin (Mevacor), simvastatin (Zocor), and pravastatin (Pravachol).

Cholesterol-lowering-agent myopathy (CLAM) was recently reviewed by London *et al.* [67••], who presented an additional case and proposed that the early development of myotonic discharges and myopathic symptomatology may be caused by an increase in muscle 'membrane fluidity', the freedom of motion within the phospholipid membrane bi-layer [68]. Because cholesterol is the major sterol constituent of muscle membranes, reduction of the normal cholesterol pool available for membrane synthesis can increase membrane fluidity. This may result in unstable sarcolemma, myotonic discharges, and increased levels of sarcoplasmic enzymes or myoglobinuria [67••].

Although a transient increase in serum creatine kinase levels is common after treatment with lovastatin, the drug has been associated with clinically overt myopathic symptoms in fewer than 1% of the patients treated. Combined drug use increases the risk of myopathy. When cyclosporin is co-administered with lovastatin to patients with a heart or kidney transplant and hyperlipidemia, the incidence of myopathy with hyperCKemia or myoglobinuria may increase by as much as 30%. These figures may, however, be viewed cautiously, because when cyclosporin is administered alone, there have been cases of histologically proven and reversible myopathy [69,70•].


Four different HMG-CoA-reductase inhibitors (lovastatin, simvastatin, pravastatin, and L647318), produced in Sprague-Dawley rats a dose-related myocytotoxicity documented histologically [71•]. The myopathy was potentiated by cyclosporin. Doses of the HMG-CoA reductase inhibitors that did not produce muscle toxicity when given alone increased the incidence of myopathy by 75 and 100% when co-administered with cyclosporin [71•].

**Blocking agent–corticosteroid myopathy**


Patients with prolonged paralysis induced with non depolarizing blocking agents, such as pancuronium, may manifest an acute myopathy. Most of these patients have received high doses of corticosteroids to treat status asthmaticus [72] or some other systemic illness for which artificial paralysis was induced to secure an aggressive pulmonary toilette, as reviewed by Danon and Carpenter [73••]. The combination of blocking agents and corticosteroids has been consistently implicated in the development of this myopathy, which can be called blocking agent–corticosteroid myopathy. The clinical presentation is rather typical and characterized by severe generalized quadric paresis, muscle wasting, normal or moderately el-

evated creatine kinase levels, and myopathic changes on the electromyogram. The weakness usually improves, but slowly. We have seen three cases of blocking agent–corticosteroid myopathy at the National Institutes of Health in the past 3 years, and at least 20 cases have been reported [73••]. Muscle biopsy shows severe morphologic abnormalities characterized by central empty areas, like autolysis, but without signs of necrosis, inflammation, or phagocytosis (Fig. 1). With adenosine triphosphate (ATP)ase staining, striking areas of central pallor are seen in many fibers (Fig. 2).

The histologic hallmark of blocking agent–corticosteroid myopathy is selective and extensive loss of thick myofilaments with preservation of the thin myofilaments and Z



**Fig. 1.** Transverse section of a muscle biopsy from one of our patients with blocking agent–corticosteroid myopathy. Trichrome staining shows large, irregular, unstained empty areas without an associated cellular reaction corresponding to focal loss of myofibrils. Some fibers have dark smudgy areas, probably representing accumulations of disorganized myofilaments or Z-disc streaming ( $\times 680$ ).



**Fig. 2.** Muscle biopsy from one of our patients with blocking agent–corticosteroid myopathy. Adenosine triphosphate (ATP)ase staining (pH 9.4) shows central or irregular and patchy areas of extensive loss of filaments in both fiber types ( $\times 425$ ).

discs [73••]. These changes resemble those observed in denervated rats treated with high doses of steroids [74]. High doses of steroids should, therefore be used with caution in patients receiving paralytic agents for prolonged periods.

Acute external ophthalmoplegia has also been seen in blocking agent–corticosteroid myopathy [75•]. In these cases, a differential diagnosis should include myasthenia gravis, Guillain-Barré syndrome (Miller-Fisher variant), Wernicke's encephalopathy, and phenytoin intoxication.

## Conclusion

Advances in immunocytochemistry, immunology, and molecular virology have increased our understanding of the immunopathogenesis of inflammatory myopathies. Recent observations suggest that retroviruses appear to be the most promising candidate viruses capable of triggering an inflammatory myopathy. The cellular mechanisms of myotoxicity related to AZT, the cholesterol-lowering drugs and the combination of blocking agents with steroids, have been defined. Awareness of myocytotoxicity of these drugs has begun to have and impact on medical therapeutics.

## References and recommended reading

Papers of particular interest, published within the annual period of review, have been highlighted as:

- of special interest
- of outstanding interest

1. DALAKAS MC: Polymyositis, Dermatomyositis, and Inclusion-body Myositis. *N Engl J Med* 1991, 325:1487–1498.  
•• The current status on the pathogenesis, diagnosis, classification, and treatment of inflammatory myopathies is reviewed. New diagnostic criteria are provided, and common errors and misconceptions are discussed from the point of view of the author's experience with a large number of patients.
2. BOHAN A, PETER JB: Polymyositis and Dermatomyositis. *N Engl J Med* 1975, 292:334–347.
3. KISSEL JT, MENDELL JR, RAMMOHAN KW: Microvascular Deposition of Complement Membrane Attack Complex in Dermatomyositis. *N Engl J Med* 1986, 314:329–334.
4. EMSLIE-SMITH AM, ENGEL AG: Microvascular Changes in Early and Advanced Dermatomyositis: A Quantitative Study. *Ann Neurol* 1990, 27:343–356.
5. EUWER RL, SOUTHEIMER RD: Amyopathic Dermatomyositis (Dermatomyositis Siné Myositis). *J Am Acad Dermatol* 1991, 24:959–966.  
• There was no clinical or serological evidence of myopathy during a 2-year follow-up of six patients with DM who presented to a dermatology clinic with the characteristic skin rash and muscle weakness.
6. OTERO C, JILA I, DALAKAS M: Is There Dermatomyositis (DM) Without Myositis? [Abstract] *Neurology* 1992, 42(suppl):388.
7. CERVERA R, RAMIREZ G, FERNANDEZ-SOLA J, D'CRUZ D, CASADEMONT J, GRAU JM, ASHERSON RA, KHAMASHTA MA, MARQUES A, HUGHES GRV: Antibodies to Endothelial Cells in Dermatomyositis: Association with Interstitial Lung Disease. *BMJ* 1991, 302:880–881.

Of 18 patients with DM, eight had immunoglobulin G or immunoglobulin M antibodies to endothelial cells, and six of them had interstitial lung disease.

8. ARAHATA K, ENGEL AG: Monoclonal Antibody Analysis of Mononuclear Cells in Myopathies. V: Identification and Quantification of T8<sup>+</sup> Cytotoxic And T8<sup>+</sup> Suppressor Cells. *Ann Neurol* 1988, 23:493–499.
9. EMSLIE-SMITH AM, ARAHATA K, ENGEL AG: Major Histocompatibility Complex Class I Antigen Expression, Immunolocalization of Interferon Subtypes and T-Cell-Mediated Cytotoxicity in Myopathies. *Hum Pathol* 1989, 20:224–231.
10. HOHLFELD R, ENGEL AG: Coculture with Autologous Myotubes of Cytotoxic T Cells Isolated from Muscle in Inflammatory Myopathies. *Ann Neurol* 1991, 29:498–507.  
•• Cell lines expanded from 20 patients with inflammatory myopathies expressed T-cell antigens and exhibited a low but significant cytotoxicity against autologous myotubes. This important study demonstrates that endomysial lymphocytes are cytotoxic by recognizing a still undefined muscle auto-antigen.
11. HOHLFELD R, ENGEL AG, LI K, HARPER MC: Polymyositis Mediated by T Lymphocytes that Express the  $\gamma/\delta$  Receptor. *N Engl J Med* 1991, 324:877–881.
12. EMSLIE-SMITH AM, ENGEL AG: Necrotizing Myopathy with Pipestem Capillaries, Microvascular Deposition of the Complement Membrane Attack Complex (MAC) and Minimal Cellular Infiltration. *Neurology* 1991, 41:936–939.  
•• A distinct myopathy, with 'pipestem' thick vessels, focal capillary depletion, and MAC deposits, is described in three patients. An immune-mediated microangiopathy is proposed for the pathogenesis of this myopathy, which has different clinical and histological features from the other forms of inflammatory myopathies.
13. CALLEN JP: Malignancy in Polymyositis/Dermatomyositis. *Clin Dermatol* 1988, 2:55–63.
14. SIGURGEIRSSON B, LINDELOF B, EDHOG O, ALLANDER E: Risk of Cancer in Patients with Dermatomyositis or Polymyositis: A Population-Based Study. *N Engl J Med* 1992, 326:363–367.  
• An increased incidence of cancer was found in patients with PM and DM admitted in various Swedish hospitals from 1963–1983 when they were compared with cancer patients from the Swedish Cancer Registry. Although the association of DM with cancer was confirmed, the study did not convincingly demonstrate an association with PM because of various methodological deficiencies in the study design.
15. NEVILLE HE, BAUMBACH IL, RINGEL SP, RUSSO LS, SUJANSKY E, GARCIA CA: Familial Inclusion Body Myositis: Evidence for Autosomal Dominant Inheritance. *Neurology* 1992, 42:897–902.  
• This is the first report of a dominantly inherited IBM in a kindred affecting multiple members in two generations.
16. WELANDER L: Myopathia Distalis Tarda Hereditaria. *Acta Med Scand* 1951, 141:1–124.
17. LINDBERG C, BORG K, EDSTRÖM L, HEDSTRÖM A, OLDFORS A: Inclusion Body Myositis and Welerand Distal Myopathy: A Clinical Neurophysiological and Morphological Comparison. *J Neurol Sci* 1991, 103:76–81.  
• Comparison of five Welerand's hereditary distal myopathy patients with five IBM patients matched for age showed that both share common histologic features of rimmed vacuoles and 15–18 nm filaments. Endomysial inflammation, involvement of proximal muscles, and a more severe course distinguished IBM from the distal myopathy.
18. MENDELL JR, SAHENK Z, GALES T, PAUL L: Amyloid Filaments in Inclusion Body Myositis. Novel Findings Provide Insight into Nature of Filaments. *Arch Neurol* 1991, 48:1229–1234.  
•• With Congo-red staining, green bi-refringent amyloid deposits were found adjacent to the vacuoles, and rarely perivascularly, in some muscle fibers of IBM patients. The location of amyloid deposits corresponded to the characteristic 15–18 nm filaments, which had ultrastructural characteristics similar to the classic amyloid fibrils. Amyloid material may be formed intracellularly and represent a modification of a normal protein within an acidic degradative vacuolar compartment.



19. ASKANAS V, ENGEL WK, ALVAREZ RB, GLENNER GG: **βAmyloid Protein Immunoreactivity in Muscle of Patients with Inclusion-Body Myositis.** *Lancet* 1992, 339:560–561.  
The amyloid deposits within the vacuolated fibers of IBM patients immunoreacted with antibodies to β-amyloid protein, the protein sequenced from the amyloid fibers of Alzheimer's disease. Beta-amyloid protein co-localized with ubiquitin.
20. ASKANAS V, SERDAROGLU P, ENGEL WK, ALVAREZ RB: **Immunolocalization of Ubiquitin in Muscle Biopsies of Patients with Inclusion Body Myositis and Oculopharyngeal Muscular Dystrophy (OPMD).** *Neurosci Lett* 1991, 130:73–76.  
The vacuolated muscle fibers of patients with both IBM and oculopharyngeal muscular dystrophy contained ubiquitin. The 15–21 nm cytoplasmic tubulofilaments, characteristic for IBM, also immunoreacted with ubiquitin.
21. HERSHKO A: **Ubiquitin-Mediated Protein Degradation.** *J Biol Chem* 1988, 263:15237–15240.
22. MAZURKIEWICZ JE: **Ubiquitin Deposits are Present in Spinal Motor Neurons in all Stages of the Disease in the Motor Neuron Degeneration (MND) Mutant of the Mouse.** *Neurosci Lett* 1991, 128:182–186.
23. GOFFIN Y: **Microscopic Amyloid Deposits in the Heart Valves: A Common Local Complication of Chronic Damage and Scarring.** *J Clin Pathol* 1980, 33:262–268.
24. LEFF RL, BURGESS SH, MILLER FH, LOVE TA, TARGOFF IN, DALAKAS MC, JOFFEE MM, PLOTZ PH: **Seasonal Onset of Adult Idiopathic Inflammatory Myopathy in Patients with Anti-Jo-1 and Anti-Signal Recognition Particle Antibodies.** *Arthritis Rheum* 1991, 11:1391–1396.
25. LEFF RL, LOVE LA, MILLER FW, GREENBERG SJ, KLEIN EA, DALAKAS MC, PLOTZ PH: **Viruses in the Idiopathic Inflammatory Myopathies Absence of Candidate Viral Genomes in Muscle.** *Lancet* 1992, 339:1192–1195.  
With use of the polymerase chain reaction, no viral nucleic acid sequences for Coxsackie virus, mumps, adenoviruses, HIV, HTLV-I, and HTLV-II were detected in the muscle biopsies of 44 patients with inflammatory myopathies.
26. DALAKAS MC, PEZESHKPOUR GH: **Neuromuscular Diseases Associated with Human Immunodeficiency Virus Infection.** *Ann Neurol* 1988, 23(suppl):S38–S48.
27. DALAKAS M, ILLA I: **HIV-Associated Myopathies.** In *Pediatric AIDS*. Edited by Pizzo A, Wilfelt CM. Baltimore: Williams & Wilkins, 1991:420–429.
28. ILLA I, NATH A, DALAKAS MC: **Immunocytochemical and Virological Characteristics of HIV-Associated Inflammatory Myopathies: Similarities with Seronegative Polymyositis.** *Ann Neurol* 1991, 29:474–481.  
The major endomysial inflammatory cell in patients with HIV-PM was the CD8<sup>+</sup> cell which surrounded or invaded healthy and MHC-I antigen-expressing muscle fibers. HIV antigens were seen only in occasional lymphoid cells, but not within the muscle fibers. These findings were identical to PM in HIV-negative patients. Retroviruses can trigger an inflammatory myopathy via a T-cell-mediated cytotoxic process triggered by the virus.
29. LAMPERTH L, ILLA I, DALAKAS M: **In Situ Hybridization in Muscle Biopsies from Patients with HIV-Associated Polymyositis (HIV-PM) Using Labeled HIV-RNA Probes.** *Neurology* 1990, 40(suppl 1):121.
30. LEON-MONZON MEL, DALAKAS M: **Detection of HIV in Muscle and Nerve Biopsies by DNA-Amplification Techniques.** *Neurology* 1991, 41(suppl 1):376.  
With use of the polymerase chain reaction in serial sections of muscle biopsies from patients with HIV-PM, HIV amplification products were seen only in two out of 12 patients and only in 2 out of 10 4 μm-thick serial sections, suggesting that amplified HIV products are not within the muscle fibers but in rare endomysial lymphoid cells.
31. HANTAI D, FOURNIER JG, VAZEUX R, COLLIN H, BAUDRIMONT M, FARDEAU M: **Skeletal Muscle Involvement in Human Immunodeficiency Virus Infection.** *Acta Neuropathol* 1991, 81:496–502.  
*In situ* hybridization and immunocytochemistry on seven muscle biopsy specimens from HIV-positive patients with myopathy showed HIV signals in isolated endomysial mononuclear cells, but not within the muscle fibers, in only one patient.
32. DALAKAS M, LEON-MONZON M, ILLA I, RODGERS-JOHNSON P, MORGAN O: **Immunopathology of HTLV-I-Associated Polymyositis (HTLV-PM): Studies in 6 Patients.** *Neurology* 1992, 42(suppl):301–302.  
Immunocytochemical studies in seven patients with HTLV-I-PM showed that the initiation of the muscle fiber injury is mediated by CD8<sup>+</sup> cytotoxic T cells in the context of MHC-I expression by the muscle fibers.
33. RUCHETON M, GRAAFLAND H, FANTON H, URSULE L, FERRIER P, LARSEN CJ: **Presence of Circulating Antibodies Against gag-Gene MuLV Proteins in Patients with Autoimmune Connective Tissue Disorders.** *Virology* 1985, 144:468–480.
34. LAMPERTH L, VINCENZI E, DALAKAS M: **Infection and Transfection of Human Muscle by HIV Proviral-DNA Construct.** *Neurology* 1991, 41(suppl 1):211.  
Human myotubes in culture were resistant to infection with intact HIV to transfection with HIV-proviral DNA and to infection with HIV-positive macrophages.
35. BOTHE K, AGUZZI A, LASSMANN H, RETHWILM A, HORAK I: **Progressive Encephalopathy and Myopathy in Transgenic Mice Expressing Human Foamy Virus Genes.** *Science* 1991, 253:555–557.  
A destructive myopathy developed in transgenic mice carrying the *bel* region of the human foamy retrovirus. The transgene was expressed in the striated muscle.
36. SCHWARTZMAN WA, LAMPERTUS MW, KENNEDY CA, GOETZ MB: **Staphylococcal Pyomyositis in Patients Infected with the Human Immunodeficiency Virus.** *Am J Med* 1991, 90:595–600.  
Five cases of pyomyositis caused by staphylococcal infection presented with low-grade fever, without leukocytosis, and localized pain and swelling in the muscle. No previous trauma or risk factors were identified. Defects in neutrophil function are implicated.
37. WIDROW CA, KELLIE SM, SALTZMAN BR, MATHUR-WAGH U: **Pyomyositis in Patients with Human Immunodeficiency Virus: An Unusual Form of Disseminated Bacterial Infection.** *Am J Med* 1991, 91:129–136.  
Six cases of pyomyositis, one caused by gram-negative bacteria, are described.
38. LACROIX C, SAID G: **Muscle Siderosis in AIDS: A Marker for Macrophage Dysfunction?** *J Neurol* 1992, 239:46–48.  
Iron granules were found in the endomysial macrophages in 21 out of 41 AIDS patients with myopathy. Dysfunction of the macrophages, which cannot remove the iron produced by degradation of myoglobin, was suggested.
39. KEIM DR, HERNANDEZ RJ, SULLIVAN DB: **Serial Magnetic Resonance Imaging in Juvenile Dermatomyositis.** *Arthritis Rheum* 1991, 34:1580–1584.  
A patient with DM was followed with serial MRIs. High-intensity T<sub>2</sub>-weighted images returned to normal when the disease remitted.
40. FUJINO H, KOBAYASHI T, GOTO I, ONITSUKA H: **Diagnostic Resonance Imaging of the Muscles in Patients with Polymyositis and Dermatomyositis.** *Muscle Nerve* 1991, 14:716–720.  
High-intensity T<sub>2</sub>-weighted images were observed in patients with acute PM or DM. These images reverted after successful therapy.
41. HERNANDEZ RJ, KEIM DR, CHENEVERT TL, SULLIVAN DB, AISER AM: **Fat-Suppression MR Imaging of Myositis.** *Radiology* 1992, 182:217–219.  
A fat-suppressing imaging technique increased resolution and may be useful in the evaluation of the muscles in patients with inflammatory myopathies.
42. FRAZER DD, FRANK JA, DALAKAS M, MILLER FW, HICKS JF, PLOTZ PH: **Magnetic Resonance Imaging in the Idiopathic Inflammatory Myopathies.** *J Rheumatol* 1991, 18:1693–1700.



MRI, using the fat-suppressing technique, correlated with disease activity determined by muscle biopsy.

43. FLECKENSTEIN JL, BURNS DK, MURPHY FK, JAYSON HT, BONTE FJ: **Differential Diagnosis of Bacterial Myositis in AIDS: Evaluation with MR Imaging.** *Radiology* 1991, 179:653-658.

Radiologic patterns distinguishing pyomyositis from other conditions causing soft tissue swelling in AIDS patients are provided. Abscesses within the muscle, as seen in pyomyositis, spare the subcutaneous tissues and can be differentiated from cellulitis, lymphedema, muscle lymphoma, sarcoma, or venous thrombosis, where both the muscle and the subcutaneous tissues are involved.

44. MILLER FW, LEITMAN SF, CRONIN ME, HICKS JE, LEFF RL, WESLEY R, FRASER DD, DALAKAS MC, PLOTZ PH: **Controlled Trial of Plasma Exchange and Leukopheresis in Polymyositis and Dermatomyositis.** *N Engl J Med* 1992, 326:1380-1384.

Plasmapheresis or leukopheresis was ineffective in a double-blind controlled study of 39 patients with chronic PM or DM.

45. LUECK CJ, TREND P, SWASH M: **Cyclosporin in the Management of Polymyositis and Dermatomyositis.** *J Neurol Neurosurg Psychiatry* 1991, 54:1007-1008.

Cyclosporin, added to their therapeutic regimen, was beneficial in four patients with PM or DM.

46. LANG BA, LAXER RM, MURPHY G, SILVERMAN ED, ROIFMAN CM: **Treatment of Dermatomyositis with Intravenous Immunoglobulin.** *Am J Med* 1991, 91:169-172.

In a 9-month uncontrolled clinical trial, five patients with juvenile DM responded to monthly infusions of high-dose intravenous immunoglobulin.

47. CHERIN P, HERSON S, WECHSLER B, PIETTE JC, BLETRY O, COUTELLIER A, ZIZA JM, GODEAU P: **Efficacy of Intravenous Immunoglobulin Therapy in Chronic Refractory Polymyositis and Dermatomyositis: An Open Study with 20 Adult Patients.** *Am J Med* 1991, 91:162-168.

A total of 20 patients, six with DM and 14 with PM refractory to available therapies, were treated over a mean period of 4 months with high-dose intravenous immunoglobulin. In 16 of the patients, intravenous immunoglobulin increased their strength and reduced the serum muscle enzymes.

48. VERNA A, BRADLEY WG, ADESINA AM, SOFFERMAN R, PENBELBURY WW: **Inclusion Body Myositis with Cricopharyngeus Muscle Involvement and Severe Dysphagia.** *Muscle Nerve* 1991, 14:470-473.

The dysphagia in a patient with IBM improved after cricopharyngeal myotomy.

49. DARROW DH, HOFFMAN HT, BARNES GJ, WILEY CA: **Management of Dysphagia in Inclusion Body Myositis.** *Arch Otolaryngol Head Neck Surg* 1992, 118:313-317.

The pathophysiologic nature of dysphagia in IBM and guidelines for cricopharyngeal myotomy are presented in a patient who improved after myotomy.

50. DALAKAS MC, ILLA I, PEZESHKPOUR GH, LAUKAITIS JP, COHEN B, GRIFFIN JL: **Mitochondrial Myopathy Caused by Long-Term Zidovudine Therapy.** *N Engl J Med* 1990, 322:1098-1105.

51. PEZESHKPOUR GH, ILLA I, DALAKAS MC: **Ultrastructural Characteristics of DNA Immunocytochemistry in HIV and AZT-Associated Myopathies.** *Hum Pathol* 1991, 11:1281-1288.

Electron microscopic changes in the mitochondria were seen in the muscle biopsies of the AZT-treated patients but not in the muscles of patients with HIV myopathy. With immunocytochemistry, absence or reduction of immunostainable mtDNA, compared with the normal nuclear DNA, was noted only in the muscles of patients with AZT myopathy.

52. CHALMERS AC, GRECO CM, MILLER RG: **Prognosis in AZT Myopathy.** *Neurology* 1991, 41:1181-1184.

In 20 patients with AZT myopathy, myalgia resolved, muscle strength normalized or improved, and spontaneous activity on the electromyogram decreased or disappeared 4 to 6 weeks after AZT was discontinued.

53. JAY C, ROPKA M, HENCH K, GRADY C, DALAKAS M: **Prospective Study of Myopathy During Prolonged Low-Dose AZT:**

**Clinical Correlates of AZT Mitochondrial Myopathy (AZT-MM) and HIV-Associated Inflammatory Myopathy (HIV-IM) [Abstract].** *Neurology* 1992, 42(suppl):146.

54. MIHRI C, BAUDRIMONT M, BONNE G, GENY C, DEGOUL F, MARSAC C, ROUILLET E, GHERARDI R: **Zidovudine Myopathy: A Distinctive Disorder Associated with Mitochondrial Dysfunction.** *Ann Neurol* 1991, 29:606-614.

A myopathy with abnormal mitochondria developed in 13 patients who received high-dose AZT therapy. The mitochondrial succinate cytochrome c reductase and cytochrome c oxidase were reduced, but the citrate synthase remained normal.

55. ARNAUDO E, DALAKAS M, SHANSKE S, MORAES CT, DIMAURO S, SCHON EA: **Depletion of Muscle Mitochondrial DNA in AIDS Patients with Zidovudine-Induced Myopathy.** *Lancet* 1991, 337:508-510.

With Southern blotting on the extracted DNA from the muscle of patients with AZT myopathy, up to 78% depletion of the mtDNA was noted, compared with unaffected nuclear DNA. Depletion of the muscle mtDNA was related to the AZT-induced inhibition of the  $\gamma$ -DNA polymerase causing termination of the DNA chain.

56. WEISSMAN JD, CONSTANTINIS I, HUDGINS P, WALLACE DC: **<sup>31</sup>P Magnetic Resonance Spectroscopy Suggests Impaired Mitochondrial Function in AZT-Treated HIV-Infected Patients.** *Neurology* 1992, 42:519-623.

Using an exercise <sup>31</sup>P magnetic resonance spectroscopy protocol, the authors found delay in the recovery of phosphocreatine in the muscles of AZT-treated patients. This is consistent with impaired oxidative metabolism of muscle mitochondria.

57. SOUEIDAN S, SINNEWELL T, JAY C, FRANK J, MCLAUGHLIN A, DALAKAS M: **Impaired Muscle Energy Metabolism in Patients with AZT-myopathy: A Blinded Comparative Study of Exercise <sup>31</sup>P Magnetic Resonance Spectroscopy (MRS) with Muscle Biopsy [Abstract].** *Neurology* 1992, 42(suppl):146.

58. LAMPERTH L, DALAKAS MC, DAGANI F, ANDERSON J, FERRARI R: **Abnormal Skeletal and Cardiac Muscle Mitochondria Induced by Zidovudine (AZT) in Human Muscle *In Vitro* and in an Animal Model.** *Lab Invest* 1991, 65:742-751.

Human myotubes in tissue culture demonstrated proliferation and ultrastructural abnormalities of mitochondria after 19 days of AZT treatment. Healthy rats injected with AZT developed elevated creatine kinase levels, hyperlactacidemia, weight loss, and abnormal skeletal and heart mitochondria. Isolated muscle mitochondria had decreased state three respiration, reduced rotenone-sensitive nicotinamide adenine dinucleotide-cytochrome c reductase and were uncoupled. AZT was highly concentrated in the skeletal and cardiac muscle.

59. HERZBERG NH, ZORN I, ZWART R, PORTEGRIS P, BOLHUIS PA: **Major Growth Reduction and Minor Decrease in Mitochondrial Enzyme Activity in Cultured Human Muscle Cells After Exposure to Zidovudine.** *Muscle Nerve* 1992, 15:706-710.

AZT caused marked inhibition of cell proliferation of human muscle cultures. The nuclear-encoded mitochondrial citrate synthase was normal but mitochondrial-DNA-encoded cytochrome c oxidase was decreased.

60. LEWIS W, PAPOIAN T, GONZALEZ B, LOUIE H, KELLY DP, PAYNE RM, GRODY WW: **Mitochondrial Ultrastructural and Molecular Changes Induced by Zidovudine in Rat Hearts.** *Lab Invest* 1991, 65:228-236.

AZT-fed rats developed cardiac toxicity with ultrastructural changes of abnormal cardiac muscle mitochondria. The mitochondrial RNA was decreased and the cytochrome mRNA was selectively depressed, whereas the nuclear-encoded mRNAs on the mRNAs that encode polypeptides translocated into mitochondria, were normal.

61. LEWIS W, GONZALEZ B, CHOMYN A, PAPOIAN T: **Zidovudine Induces Molecular Biochemical and Ultrastructural Changes in Rat Skeletal Muscle Mitochondria.** *J Clin Invest* 1992, 89:1354-1360.

After 35 days, AZT-fed rats developed morphologic abnormalities in their skeletal muscle mitochondria associated with a decrease in mtDNA, and mitochondrial polypeptide synthesis. The cytosolic glyceraldehyde-3-phosphate dehydrogenase and the sarcomeric mitochondrial creatine kinase mRNA remained normal.

62. MORAES CT, SHANSKE S, TRITSCHLER HJ, APRILLE JR, ANDRETTA F, BONILLA E, SCHON EA, DIMAURO S: **mtDNA Depletion with Variable Tissue Expression: A Novel Genetic Abnormality in Mitochondrial Diseases.** *Am J Hum Genet* 1991, 48:492-501.
63. PIERCE LR, WYSOWSKI DK, GROSS TP: **Myopathy and Rhabdomyolysis Associated with Lovastatin-Gemfibrozil Combination Therapy.** *JAMA* 1990, 264:71-75.
64. BLANE GF: **Comparative Toxicity and Safety Profile of Fenofibrate and Other Fibric Acid Derivatives.** *Am J Med* 1987, 83(suppl 5B):26-36.
65. LITIN SC, ANDERSON CF: **Nicotinic Acid-Associated Myopathy: A Report of Three Cases.** *Am J Med* 1989, 86:481-483.
66. NORMA DJ, ILLINGWORTH DR, MUNSON J, HOSENPUD J: **Myolysis and Acute Renal Failure in Heart-Transplant Recipient Receiving Lovastatin.** *N Engl J Med* 1988, 318:46-47.
67. LONDON SF, GROSS KF, RINGEL SP: **Cholesterol-Lowering Agent Myopathy (CLAM).** *Neurology* 1991, 41:1159-1160.  
Describes a case of CLAM myopathy. The authors proposed the term CLAM and suggest that the pathogenesis of the myopathy may be related to lowering of the normal cholesterol pool available for membrane synthesis. This, in turn, increases the muscle membrane fluidity, resulting in unstable sarcolemma, myotonic discharges, and increased levels of sarcoplasmic enzymes or rhabdomyolysis.
68. BREGESTOVSKI PD, BOLOTINA VN: **Membrane Fluidity and Kinetics of  $Ca^{2+}$  Dependent Potassium Channels.** *Biomed Biochim Acta* 1989, 48:S382-S387.
69. SOLA FJ, CAMPISTOL J, CASADEMONT J, GRAU JM, URBANO-MARQUEZ A: **Reversible Cyclosporin Myopathy.** *Lancet* 1990, i:362-363.
70. ARELLANO F, KRUPP P: **Muscular Disorders Associated with Cyclosporin.** *Lancet* 1991, 337:915-916.  
Two types of myopathic syndromes can occur with the use of cyclosporin: one is a dose-dependent myopathy characterized by myalgia and weakness; the other is myopathy with hyperCKemia or myoglobinuria when cyclosporin is combined with lovastatin.
71. SMITH PF, EYDELLOTH RS, GROSSMAN SJ, STUBBS JR, SCHWARTZ MS, GEMERSHANSEN JI, VYAS KP, KARI PH, MACDONALD JS: **HMG-CoA Reductase Inhibitor-Induced Myopathy in the Rat: Cyclosporin A Interaction and Mechanism Studies.** *J Pharmacol Exp Ther* 1991, 257:1225-1235.  
Development of a dose-dependent myopathy characterized by skeletal muscle degeneration was noted with four different HMG-CoA reductase inhibitors in Sprague-Dawley rats. Non-myotoxic doses of these drugs caused myopathy when co-administered with cyclosporin. The myotoxicity of the drugs was potentiated by cyclosporin.
72. DESMET Y, JAMINET M, JAEGER U, JACOB J, NEURAY H, HAUS G, LEDSCH-CAMUS D, MEYERS R: **Myopathie Aiguë Cortisonique de l'Asthmatique.** *Rev Neurol (Paris)* 1991, 147:682-685.
73. DANON MJ, CARPENTER S: **Myopathy with Thick Filament (Myosin) Loss Following Prolonged Paralysis with Vecuronium During Steroid Treatment.** *Muscle Nerve* 1991, 14:1131-1139.  
Describes a case of blocking agent-corticosteroid myopathy. Histologically the authors found extensive loss of thick (myosin) filaments; changes which resemble those observed in experimental myopathy in denervated rats treated with corticosteroids.
74. ROULEAU G, KARPATI G, CARPENTER S: **Glucocorticoid Excess Induces Preferential Depletion of Myosin in Denervated Skeletal Muscle Fibers.** *Muscle Nerve* 1987, 10:428-438.
75. SITWELL LD, WEINSHENKER BG, MONPETIT V, REID D: **Complete Ophthalmoplegia as a Complication of Acute Corticosteroid and Pancuronium-Associated Myopathy.** *Neurology* 1991, 41:921-922.  
Describes a case of blocking agent-corticosteroid myopathy with ophthalmoplegia.

---

Marinos C. Dalakas, Neuromuscular Diseases Section, NINDS, Building 10, Room 4N248, National Institutes of Health, 9000 Rockville Pike, Bethesda, Maryland 20892, USA.